532 related articles for article (PubMed ID: 17438182)
21. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
23. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.
Fargnoli MC; Altobelli E; Keller G; Chimenti S; Höfler H; Peris K
Melanoma Res; 2006 Apr; 16(2):175-82. PubMed ID: 16567973
[TBL] [Abstract][Full Text] [Related]
24. Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
[TBL] [Abstract][Full Text] [Related]
25. High- and low-penetrance cutaneous melanoma susceptibility genes.
Fargnoli MC; Argenziano G; Zalaudek I; Peris K
Expert Rev Anticancer Ther; 2006 May; 6(5):657-70. PubMed ID: 16759158
[TBL] [Abstract][Full Text] [Related]
26. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
29. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
de Torre C; Martínez-Escribano J
Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
[TBL] [Abstract][Full Text] [Related]
30. Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants.
Li C; Liu T; Tavtigian SV; Boucher K; Kohlmann W; Cannon-Albright L; Grossman D
Melanoma Res; 2020 Jun; 30(3):247-251. PubMed ID: 31567591
[TBL] [Abstract][Full Text] [Related]
31. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
32. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
[No Abstract] [Full Text] [Related]
34. CDKN2A mutations in melanoma families from Uruguay.
Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
[TBL] [Abstract][Full Text] [Related]
35. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
[TBL] [Abstract][Full Text] [Related]
36. The Y152X MC1R gene mutation: occurrence in ethnically diverse Jewish malignant melanoma patients.
Galore G; Azizi E; Scope A; Pavlotsky F; Yakobson E; Friedman E
Melanoma Res; 2007 Apr; 17(2):105-8. PubMed ID: 17496785
[TBL] [Abstract][Full Text] [Related]
37. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
38. High incidence of primary melanomas in an MC1R RHC homozygote/CDKN2A mutant genotype patient.
Sinnya S; Jagirdar K; De'Ambrosis B; McMeniman E; Sturm RA; Soyer HP
Arch Dermatol Res; 2015 Oct; 307(8):741-5. PubMed ID: 26103950
[TBL] [Abstract][Full Text] [Related]
39. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic carcinoma surveillance in patients with familial melanoma.
Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]